ODYS posts Q3 revenue decline; ends Q3 with $29.8M cash
Odysight.ai (ODYS) reported Q3 2025 results showing sharply lower quarterly revenue and higher operating expenses, offset by a stronger cash position following a February equity raise. Revenue was $149 thousand in Q3 2025, down from $1.292 million a year ago. Gross profit was $23 thousand versus $405 thousand. The company posted an operating loss of $4.707 million and a net loss of $4.416 million for the quarter.
For the nine months ended September 30, 2025, revenue was $2.576 million versus $2.660 million. Results included full derecognition of a $1.690 million contract liability tied to a Fortune 500 medical customer and a $957 thousand fulfillment asset write-off, plus a $203 thousand inventory impairment related to that customer. R&D expenses rose to $7.322 million (up 56%), sales and marketing to $1.604 million (up 99%), and G&A to $5.473 million (up 39%). Financing income was $949 thousand. Net loss for the period was $12.756 million.
Cash, cash equivalents and restricted cash were $29.813 million as of September 30, 2025. Backlog/remaining performance obligations totaled approximately $14.2 million. In February 2025, the company sold 3,653,124 shares at $6.50, generating approximately $23.7 million in gross proceeds; net proceeds were about $20.9 million. Shares outstanding were 16,355,243 as of November 12, 2025.
Positive
- None.
Negative
- None.
Insights
Q3 revenue fell sharply; liquidity improved after equity raise.
Odysight.ai reported Q3 2025 revenue of
Nine‑month results included full derecognition of a
Liquidity improved: cash, cash equivalents and restricted cash were
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission
File No.
| (Exact name of registrant as specified in its charter) |
| (State or other jurisdiction | (I.R.S. Employer | |
| of incorporation or organization) | Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
| (Registrant’s telephone number, including area code) |
| (Former name, former address and former fiscal year, if changed since last report) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| ☐ | Large accelerated filer | ☐ | Accelerated filer |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As
of November 12, 2025, the registrant had [
As used in this Quarterly Report and unless otherwise indicated, the terms “Odysight.ai,” “we,” “us,” “our,” or “our Company” refer to Odysight.ai. Unless otherwise specified, all dollar amounts are expressed in United States dollars.
ODYSIGHT.AI INC.
QUARTERLY REPORT ON FORM 10-Q
TABLE OF CONTENTS
| Page | ||
| Special Note Regarding Forward-Looking Statements | 3 | |
| PART 1-FINANCIAL INFORMATION | ||
| Item 1. | Consolidated Financial Statements (unaudited) | 4 |
| Consolidated Balance Sheets | 5 | |
| Consolidated Statements of Comprehensive Loss | 7 | |
| Statements of Stockholders’ Equity | 8 | |
| Consolidated Statements of Cash Flows | 10 | |
| Notes to Consolidated Financial Statements | 12 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 21 |
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 28 |
| Item 4. | Control and Procedures | 28 |
| PART II-OTHER INFORMATION | ||
| Item 1. | Legal proceedings | 29 |
| Item 1A. | Risk Factors | 29 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 29 |
| Item 3. | Defaults Upon Senior Securities | 29 |
| Item 4. | Mine Safety Disclosures | 29 |
| Item 5. | Other information | 29 |
| Item 6. | Exhibits | 30 |
| SIGNATURES | 31 | |
| -2- |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:
| ● | our ability to scale up upon our operations, including market acceptance of our vision-based sensor products; | |
| ● | the amount and timing of future sales; | |
| ● | our ability to meet technical and quality specifications; | |
| ● | our ability to accurately estimate the future supply and demand for the Odysight TruVision solution and changes to various factors in our supply chain; | |
| ● | the market for adoption of vision-based sensor technologies; | |
| ● | existing regulations and regulatory developments in the United States and other jurisdictions; | |
| ● | our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others; | |
| ● | the need to hire additional personnel and our ability to attract and retain such personnel; | |
| ● | our estimates regarding expenses, backlog, future revenue, capital requirements and need for additional financing; | |
| ● | our dependence on third parties; | |
| ● | our financial performance; | |
| ● | the growth of regulatory requirements and incentives; | |
| ● | risks related to product liability claims or product recalls; | |
| ● | the overall global economic environment and trade tensions, including the adoption or expansion of economic sanctions, tariffs or trade restrictions; | |
| ● | the impact of competition and new technologies; | |
| ● | our plans to continue to invest in research and develop technology for new products; | |
| ● | our plans to potentially acquire complementary businesses; | |
| ● | the impact of any resurgence of COVID-19 or any of its variants or any other pandemic on our business and on the business of our customers; | |
| ● | security, political and economic instability in the Middle East that could harm our business, including due to the current war in Israel; and | |
| ● | the increased expenses associated with being a listed public company on the Nasdaq Capital Market, or Nasdaq. |
Forward-looking statements are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management’s beliefs and assumptions, are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Important factors that may cause actual results to differ materially from current expectations including, among other things, those listed under “Risk Factors” our Annual Report on Form 10-K for the year ended December 31, 2024 (filed on March 26, 2025). Readers are urged to consider these factors carefully in evaluating the forward-looking statements. You should read our Annual Report on Form 10-K for the year ended December 31, 2024, and the documents that we reference in and have filed as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2024, completely and with the understanding that our actual future results may be materially different from what we expect.
Forward-looking statements included in this Quarterly Report on Form 10-Q speak only as of the date of this Quarterly Report on Form 10-Q. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the Securities and Exchange Commission (“SEC”) after the date of this Quarterly Report on Form 10-Q. We qualify all of our forward-looking statements by these cautionary statements.
| -3- |
Item 1. Financial Statements
ODYSIGHT.AI INC.
INTERIM FINANCIAL STATEMENTS
AS OF SEPTEMBER 30, 2025
CONSOLIDATED ODYSIGHT.AI INC.
| Page | |
| Interim Condensed Consolidated Financial Statements - in US Dollars (USD) in thousands | |
| Interim Condensed Consolidated Balance Sheets (unaudited) | 5 |
| Interim Condensed Consolidated Statements of Operations (unaudited) | 7 |
| Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity (unaudited) | 8 |
| Interim Condensed Consolidated Statements of Cash Flows (unaudited) | 10 |
| Notes to the Interim Condensed Consolidated Financial Statements | 12 |
| -4- |
ODYSIGHT.AI INC.
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Unaudited | ||||||||
| USD in thousands | ||||||||
| Assets | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | ||||||||
| Restricted cash | - | |||||||
| Restricted deposit | - | |||||||
| Accounts receivable | ||||||||
| Inventory | - | |||||||
| Other current assets | ||||||||
| Total current assets | ||||||||
| NON-CURRENT ASSETS: | ||||||||
| Contract fulfilment assets | - | |||||||
| Property and equipment, net | ||||||||
| Operating lease right-of-use assets | ||||||||
| Severance pay asset | ||||||||
| Other non-current assets | ||||||||
| Total non-current assets | ||||||||
| TOTAL ASSETS | ||||||||
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
| -5- |
ODYSIGHT.AI INC.
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Unaudited | ||||||||
| USD in thousands | ||||||||
| Liabilities and shareholders’ equity | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable | ||||||||
| Contract liabilities - short term | ||||||||
| Operating lease liabilities - short term | ||||||||
| Accrued compensation expenses | ||||||||
| Related parties | ||||||||
| Other current liabilities | ||||||||
| Total current liabilities | ||||||||
| NON-CURRENT LIABILITIES: | ||||||||
| Contract liabilities - long term | - | |||||||
| Operating lease liabilities - long term | ||||||||
| Liability for severance pay | ||||||||
| Total non-current liabilities | ||||||||
| TOTAL LIABILITIES | ||||||||
| SHAREHOLDERS’ EQUITY: | ||||||||
| Common stock, $ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| TOTAL SHAREHOLDERS’ EQUITY | ||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
| -6- |
ODYSIGHT.AI INC.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
Nine months ended September 30, | Three
months ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Unaudited | ||||||||||||||||
| USD in thousands | ||||||||||||||||
| REVENUES | ||||||||||||||||
| COST OF REVENUES | ||||||||||||||||
| GROSS PROFIT | ||||||||||||||||
| RESEARCH AND DEVELOPMENT EXPENSES | ||||||||||||||||
| SALES AND MARKETING EXPENSES | ||||||||||||||||
| GENERAL AND ADMINISTRATIVE EXPENSES | ||||||||||||||||
| OPERATING LOSS | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| FINANCING INCOME, NET | ||||||||||||||||
| NET LOSS | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net loss per ordinary share (basic and diluted, USD) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Weighted average ordinary shares (basic and diluted, in thousands) | ||||||||||||||||
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
| -7- |
ODYSIGHT.AI INC.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
Nine Months Ended September 30, 2025 (Unaudited)
| Number | Amount | capital | Deficit | Equity | ||||||||||||||||
| Common Stock | Additional paid-in | Accumulated | Total Shareholders’ | |||||||||||||||||
| Number | Amount | capital | Deficit | Equity | ||||||||||||||||
| In thousands | USD in thousands | |||||||||||||||||||
| Balance at January 1, 2025 | $ | $ | ( | ) | $ | |||||||||||||||
| Stock based compensation | - | - | - | |||||||||||||||||
| Issuance of shares upon RSU vesting | -* | -(* | ) | - | - | |||||||||||||||
| Issuance of shares, net of issuance cost | - | |||||||||||||||||||
| Options exercise | -* | - | ||||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | |||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | ( | ) | $ | ||||||||||||||
Three Months Ended September 30, 2025 (Unaudited)
| Common Stock | Additional paid-in | Accumulated | Total Shareholders’ | |||||||||||||||||
| Number | Amount | capital | Deficit | Equity | ||||||||||||||||
| In thousands | USD in thousands | |||||||||||||||||||
| Balance as of July 1, 2025 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Stock based compensation | - | - | - | |||||||||||||||||
| Issuance of shares upon RSU vesting | -* | -(* | ) | - | - | |||||||||||||||
| Options exercise | - | - | ||||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | |||||||||||||
| Balance as of September 30, 2025 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| * |
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
| -8- |
Nine Months Ended September 30, 2024 (Unaudited)
| Common Stock | Additional paid-in | Accumulated | Total Shareholders’ | |||||||||||||||||
| Number | Amount | capital | deficit | equity | ||||||||||||||||
| In thousands | USD in thousands | |||||||||||||||||||
| Balance as of January 1, 2024 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Stock based compensation | - | - | - | |||||||||||||||||
| Issuance of shares upon RSU vesting | -* | -(*) | - | - | ||||||||||||||||
| Issuance of shares | - | |||||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | |||||||||||||
| Balance as of September 30, 2024 | $ | $ | $ | ( | ) | $ | ||||||||||||||
Three Months Ended September 30, 2024 (Unaudited)
| Common Stock | Additional paid-in | Accumulated | Total Shareholders’ | |||||||||||||||||
| Number | Amount | capital | deficit | equity | ||||||||||||||||
| In thousands | USD in thousands | |||||||||||||||||||
| Balance as of July 1, 2024 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Balance | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Stock based compensation | - | - | - | |||||||||||||||||
| Issuance of shares upon RSU vesting | -* | -(*) | - | - | ||||||||||||||||
| Issuance of shares | - | |||||||||||||||||||
| Issuance of shares, net of issuance cost | - | |||||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | |||||||||||||
| Balance as of September 30, 2024 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Balance | $ | $ | $ | ( | ) | $ | ||||||||||||||
| * |
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
| -9- |
ODYSIGHT.AI INC.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
Nine months ended September 30, | Three months ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Unaudited | ||||||||||||||||
| USD in thousands | ||||||||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||||||||||
| Net loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Adjustments to reconcile net loss to net cash used in operations: | ||||||||||||||||
| Depreciation | ||||||||||||||||
| Stock based compensation | ||||||||||||||||
| Interest and exchange differences from operating lease liability | - | ( | ) | - | ||||||||||||
| Loss (Profit) from exchange differences | ( | ) | ( | ) | ||||||||||||
| Interest income in respect of deposits | - | - | ||||||||||||||
| Changes in operating assets and liability items: | ||||||||||||||||
| Decrease (increase) in accounts receivable | ( | ) | ||||||||||||||
| Decrease in inventory | - | |||||||||||||||
| Decrease in operating lease liability | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Decrease in right-of-use asset | ||||||||||||||||
| Decrease (increase) in other current and non-current assets | ( | ) | ( | ) | ( | ) | ||||||||||
Severance pay asset and liability | - | ( | ) | - | ( | ) | ||||||||||
| Increase (decrease) in accounts payable | ( | ) | ( | ) | ||||||||||||
| Increase in related parties | ||||||||||||||||
| Decrease in contract fulfilment assets | - | |||||||||||||||
| Decrease in current and non-current contract liabilities | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Increase (decrease) in accrued compensation expenses | ( | ) | ||||||||||||||
| Increase in other current and non-current liabilities | ||||||||||||||||
| Net cash flows used in operating activities | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||||||||||
| Purchase of property and equipment | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Withdrawal of short terms deposits | - | - | ||||||||||||||
| Net cash flows provided by (used in) investing activities | ( | ) | ( | ) | ||||||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||||||||||
| Proceeds from issuance of shares, net of issuance cost (issuance cost) | ( | ) | ||||||||||||||
Proceeds from options exercise | - | |||||||||||||||
| Net cash flows provided by financing activities | ||||||||||||||||
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | ( | ) | ||||||||||||||
| BALANCE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE PERIOD | ||||||||||||||||
| EFFECT FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | ( | ) | ||||||||||||||
| BALANCE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT THE END OF THE PERIOD | ||||||||||||||||
| Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet: | ||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||
| Restricted cash | ||||||||||||||||
| Total cash, cash equivalents and restricted cash | ||||||||||||||||
| -10- |
Non-cash activities -
Nine months ended September 30, | Three months ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Unaudited | ||||||||||||||||
| USD in thousands | ||||||||||||||||
| SUPPLEMENTAL INFORMATION FOR CASH FLOW: | ||||||||||||||||
| Right-of-use assets obtained in exchange for operating lease liabilities | ||||||||||||||||
| Termination of right-of-use assets in exchange for cancellation of operating lease obligations | ( | ) | ( | ) | ( | ) | - | |||||||||
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
| -11- |
ODYSIGHT.AI INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 – GENERAL:
| a. | Odysight.ai Inc (the “Company”) was incorporated under the laws of the State of Nevada on March 22, 2013. | |
| The Company’s wholly owned subsidiary, Odysight.ai Ltd (“Odysight.ai”), was incorporated in the State of Israel on January 3, 2019, and was merged into the Company on December 31, 2019 in a share exchange transaction, following which the surviving operations of the merged entity were the operations of Odysight.ai. | ||
| On February 28, 2024, D. VIEW Ltd., a wholly owned subsidiary of the Company was incorporated in the State of Israel to act as a local representative for the defense market in Israel. | ||
| On January 9, 2025, Odysight.Ai Eu S.r.l., a wholly owned subsidiary of the Company was incorporated under the laws of Italy. | ||
| References to the Company include the subsidiaries unless the context indicates otherwise. | ||
The Company, through its subsidiaries, provides vision-based platform solutions for the Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) markets with its visualization and AI platform. The Company’s video sensor-based solutions and its embedded software, and AI algorithms are deployed in hard-to-reach locations and harsh environments across a variety of PdM and CBM use cases and allow maintenance and operations teams visibility into areas which are inaccessible under normal operation, or where the operating ambience is not suitable for continuous real-time monitoring. Some of the Company’s products utilize micro visualization technology in medical devices for minimally invasive medical procedures.
In
February 2025, the Company closed a public offering generating gross proceeds of approximately $ | ||
| On February 11, 2025, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “ODYS”. Prior to such date, the Company was quoted on the OTCQB under the same symbol. |
| -12- |
ODYSIGHT.AI INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 – GENERAL (continued):
| b. | Since
incorporation of Odysight.ai and through September 30, 2025, the Company accumulated a deficit of approximately $ |
NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
a. Unaudited Interim Financial Statements
The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
b. Principles of Consolidation
The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
c. Use of estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, inventory impairment and stock-based compensation, as well as in estimates used in applying the revenue recognition policy. Actual results may differ from those estimates.
| -13- |
ODYSIGHT.AI INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (continued):
d. Significant Accounting Policies
The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements.
NOTE 3 – LEASES:
| a. | Omer office space |
In
December 2020,
On
June 25, 2023, Odysight.ai entered into an amendment to these agreements, pursuant to which the lease for the additional space was shortened
and ended on June 30, 2023 and the lease for the original space was extended for an additional five years until December 31, 2028.
Monthly
lease payments under the agreement for the original space are approximately $
| b. | Ramat Gan office space |
In
May 2023,
Odysight.ai
subleases part of the office space in Ramat Gan to a third party for approximately $
| c. | The Company leases vehicles for the use of certain of its employees in Israel. The lease terms are typically three-year periods. |
Supplemental cash flow information related to operating leases was as follows:
SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
Nine months ended September 30, | Three months ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Unaudited | ||||||||||||||||
| USD in thousands | ||||||||||||||||
| Cash paid for amounts included in the measurement of lease liabilities | ||||||||||||||||
As
of September 30, 2025, the Company’s operating leases had a weighted average remaining lease term of
The maturities of lease liabilities under operating leases as of September 30, 2025, are as follows:
SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES
| Operating leases | ||||
| USD in thousands | ||||
| Remainder of 2025 | ||||
| 2026 | ||||
| 2027 | ||||
| 2028 | ||||
| Total future lease payments | ||||
| Less imputed interest | ( | ) | ||
| Total lease liability balance | ||||
| -14- |
ODYSIGHT.AI INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – OTHER CURRENT LIABILITIES:
Other current liabilities consisted of the following:
SCHEDULE OF OTHER CURRENT LIABILITIES
September, 2025 | December 31, 2024 | |||||||
| USD in thousands | ||||||||
| Government authorities | ||||||||
| Accrued expenses | ||||||||
| Other payables | ||||||||
| Total other current liabilities | ||||||||
NOTE 5 – EQUITY:
| a. | Private Placement | |
| 1. | On
March 29, 2021, the Company issued to certain investors, including Moshe (Mori) Arkin, a major stockholder and director of the Company,
an aggregate of | |
| 2. | On
March 16, 2023, the Company entered into stock purchase agreements for a private placement with (i) Moshe (Mori) Arkin and (ii) The
Phoenix Insurance Company Ltd. (“Phoenix Insurance”) and Shotfut Menayot Israel – Phoenix Amitim (“Phoenix
Amitim”), in connection with the sale and issuance of an aggregate of | |
| 3. | On
July 16, 2024, the Company issued | |
| 4. | On
February 12, 2025, the Company completed a U.S. underwritten public offering issuing |
Warrants:
As of September 30, 2025, the Company had the following outstanding warrants to purchase common stock:
SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK
| Warrant | Issuance
Date | Expiration
Date | Exercise
Price Per Share ($) | Number
of Underlying Common Stocks | |||||||||
| March 2021 Warrants | |||||||||||||
| March 2023 Warrants | |||||||||||||
| -15- |
ODYSIGHT.AI INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 5 – EQUITY (continued):
b. Stock-based compensation for employees, directors and service providers:
In February 2020, the Company’s Board of Directors approved the 2020 Share Incentive Plan (the “2020 Plan”).
The
2020 Plan initially included a pool of
In June 2024, the Company’s Board of Directors approved the 2024 Share Incentive Plan (the “2024 Plan”). With adoption of the 2024 Plan, the Company ceased making new awards under the 2020 Plan.
The
2024 Plan initially included a pool of
In
July 2024, the Company’s Board of Directors approved an increase to the 2024 Plan’s option pool by an additional
Also in July 2024, stockholders approved the 2024 Plan.
The 2020 Plan and 2024 Plan each provide for the grant of stock options (including incentive stock options and nonqualified stock options), shares of common stock, restricted shares, restricted share units, and other share-based awards.
Stock option activity
The fair value of each option was estimated as of the date of grant or reporting period using the Black-Scholes option-pricing model, using the following assumptions:
SCHEDULE OF FAIR VALUE OF OPTIONS ESTIMATED ASSUMPTIONS
| Nine months ended | |||||
| September 30, 2025 | |||||
| Underlying value of ordinary shares ($) | |||||
| Exercise price ($) | |||||
| Expected volatility (%) | % | ||||
| Term of the options (years) | |||||
| Risk-free interest rate | % | ||||
The
cost of the benefit embodied in the options granted during the nine months ended September 30, 2025, based on their fair value as of
the grant date, is estimated to be approximately $
The following table summarizes stock option activity for the nine months ended September 30, 2025:
SCHEDULE OF STOCK OPTION ACTIVITY
| For the | ||||||||
| Nine months ended | ||||||||
| September 30, 2025 | ||||||||
| Number of | Weighted average | |||||||
| Options | exercise price ($) | |||||||
| Outstanding at beginning of period | ||||||||
| Granted | ||||||||
| Exercised | ( | ) | ||||||
| Forfeited | ( | ) | ||||||
| Outstanding at end of period | ||||||||
| Vested at end of period | ||||||||
| -16- |
ODYSIGHT.AI INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 5 – EQUITY (continued):
Restricted stock unit (“RSU”) activity
Each RSU vests based on continued service to the Company, generally over three years. The grant date fair value of the award is recognized as stock-based compensation expense over the requisite service period. The fair value of restricted stock units was estimated on the date of grant based on the fair value of the Company’s common stock.
The following table summarizes RSU activity for the nine months ended September 30, 2025:
SCHEDULE OF RESTRICTED STOCK UNIT (“RSU”) ACTIVITY
| For the | ||||||||
| Nine months ended | ||||||||
| September 30, 2025 | ||||||||
| Number of | Weighted Average Grant Date Fair Value | |||||||
| RSUs | per Share ($) | |||||||
| Outstanding at beginning of period | ||||||||
| Granted | - | - | ||||||
| Forfeited | - | - | ||||||
| Vested | ( | ) | ||||||
| Unvested and Outstanding at end of period | ||||||||
The following table sets forth the total stock-based payment expenses resulting from options and RSUs granted, included in the statements of operation and comprehensive income:
SCHEDULE OF STOCK-BASED PAYMENT EXPENSE
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
Nine months ended September 30, | Three months ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Unaudited | ||||||||||||||||
| USD in thousands | ||||||||||||||||
| Cost of revenues | ( | ) | - | |||||||||||||
| Research and development | ||||||||||||||||
| Sales and marketing expenses | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Total expenses | ||||||||||||||||
| -17- |
ODYSIGHT.AI INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 6 – REVENUES:
| a. | Disaggregation of revenue: |
| (1) | During
the second quarter of 2022, the Company completed the development of a customer-specific project for a Fortune 500 medical company
customer (the “Client”) and moved from the project development phase to its production phase. Through March 30, 2025,
the Company recognized development services revenues and costs that had been previously deferred based on the expected manufacturing
term of the product, which the Company estimated originally at seven years. During the first quarter of 2025, due to the fact that
the Company has not received a purchase order from the Client and does not expect to receive such order, the Company decided to fully
derecognize the fulfilment asset and contract liability associated with the Client, in the amount of $ | |
| (2) | During
the nine months ended September 30, 2025, the Company recognized revenues from customization and development services in which the
performance obligation is satisfied over time in the amount of $ |
| b. | Contract fulfilment assets and Contract liabilities: |
The Company’s contract fulfilment assets and contract liabilities as of September 30, 2025, and December 31, 2024, were as follows:
SCHEDULE OF CONTRACT FULFILMENT ASSETS AND CONTRACT LIABILITIES
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| USD in thousands | ||||||||
| Contract fulfilment assets | - | |||||||
| Contract liabilities | ||||||||
Contract liabilities include deferred service and advance payments.
The change in contract fulfilment assets:
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| USD in thousands | ||||||||
| Balance at beginning of the period | ||||||||
| Contract fulfilment assets, Balance at beginning of the period | ||||||||
| Contract costs recognized during the period | ( | ) | ( | ) | ||||
| Balance at end of the period | - | |||||||
| Contract fulfilment assets, Balance at end of the period | - | |||||||
The change in contract liabilities:
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| USD in thousands | ||||||||
| Balance at beginning of the period | ||||||||
| Contract liabilities, Balance at beginning of the period | ||||||||
| Deferred revenue relating to new sales | ||||||||
| Revenue recognized during the period | ( | ) | ( | ) | ||||
| Balance at end of the period | ||||||||
| Contract liabilities, Balance at end of the period | ||||||||
Remaining Performance Obligations
Remaining
Performance Obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes deferred revenue
and amounts that are expected to be invoiced and recognized as revenue in future periods. As of September 30, 2025, the total RPO amounted
to approximately $
| -18- |
ODYSIGHT.AI INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 7 - INVENTORY:
Composed as follows:
SCHEDULE OF INVENTORY
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| USD in thousands | ||||||||
| Raw materials and supplies | - | |||||||
| Work in progress | - | |||||||
| Finished goods | - | |||||||
| Inventory gross | - | |||||||
For
the nine months ended September 30, 2025, the Company recognized an inventory impairment related to the Client in the amount of $
NOTE 8 – LOSS PER SHARE
Basic loss per share is computed by dividing net loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares as described below.
Basic net loss per share is computed based on the weighted average number of shares outstanding during each year. Diluted net loss per share is computed based on the weighted average number of shares outstanding during each year, plus the dilutive potential of the common stock considered outstanding during the year, in accordance with ASC 260-10 “Earnings per Share”.
All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the period, since all such securities have an anti-dilutive effect.
NOTE 9 - COMMITMENTS AND CONTINGENCIES
On
April 2023, the Company received approval from the Israel Innovation Authority (the “IIA”) to support and enhance the Company’s
production line and capabilities in the next 24 months until April 2025.
As of September 30, 2025, we received IIA royalty-bearing grants totalling
approximately NIS
| -19- |
ODYSIGHT.AI INC.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 10 – SEGMENT REPORTING
Segment
information is prepared on the same basis that the chief executive officer, who is the Company’s chief operating decision maker,
manages the business, makes business decisions and assesses performance. The Company has
The chief executive officer assesses performance for this segment and decides how to allocate resource. The measure of segment assets is reported on the balance sheet as total assets. The chief executive officer performs the assessment of segment performance by using the reported measure of segment profit or loss to monitor budget versus actual results.
The table below summarizes the significant expense categories regularly reviewed by the chief operating decision maker, for the nine months and three months ended September 30, 2025 and 2024:
SCHEDULE OF SEGMENT REPORTING INFORMATION
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
Nine months ended
September 30, | Three months ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Unaudited | ||||||||||||||||
| USD in thousands | ||||||||||||||||
| Revenues | ||||||||||||||||
| Cost of Sales (*) | ||||||||||||||||
| Research and Development expenses (*) | ||||||||||||||||
| Sales and marketing (*) | ||||||||||||||||
| General and Administrative expenses (*) | ||||||||||||||||
| Other segment items: | ||||||||||||||||
| Stock-based payments | ||||||||||||||||
| Depreciation | ||||||||||||||||
| Finance income, net | ||||||||||||||||
| Net loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| (*) |
| -20- |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Readers are advised to review the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2024. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements”. You should review the “Risk Factors” section of our Annual Report for the year ended December 31, 2024 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Overview
We were incorporated under the laws of the State of Nevada on March 22, 2013, under the name Intellisense Solutions Inc.
On December 30, 2019, we acquired all of the issued and outstanding share capital of ScoutCam Ltd. and, on December 31, 2029, we changed our name to ScoutCam Inc. Following this acquisition, we integrated and fully adopted the acquired miniaturized imaging business into us as our primary business activity. On June 5, 2023, we changed our name to Odysight.ai Inc.
We are a pioneer in the development, production and marketing of an innovative visualization and artificial intelligence, or AI, solution that deploys small cameras to monitor critical safety components in hard-to-reach locations and harsh environments, across various Predictive Maintenance, or PdM, and Condition Based Monitoring, or CBM, use cases.
The Odysight TruVision solution streams visual information to our processing unit, an in-platform, high-performance AI/machine learning computer, allowing maintenance and operations teams, on the ground and during operations, visibility into areas that are inaccessible under normal operating conditions or where conditions are not suitable for continuous real-time monitoring. The rich and informative data, continuously collected and analyzed by our solution on our secured cloud, provides customers with real-time failure / anomaly detection, events and data recordings, interfacing with platform mission systems and providing real-time alerts and streaming video or images, all while training our algorithms for ongoing improved accuracy and prediction capabilities. Our customers benefit from increased safety, a reduction in downtime and lower maintenance costs for their monitored platforms, using the prediction capabilities of our solution to efficiently plan maintenance work on monitored components.
Our solution aims to enhance safety and minimizes downtime by enabling real-time visual analysis of any failure occurrences. Additionally, we leverage advanced big data analytics to offer predictive insights throughout the entire system lifecycle. This includes efficient spare parts management and intelligent performance predictions, ensuring optimal system reliability and efficiency.
The Odysight TruVision solution was successfully used by NASA as we seek to reshape the aerospace, Industry 4.0, transportation and energy markets with a vison-based technology leveraging AI and machine learning to deliver innovative solutions that transform maintenance practices. As used in this Quarterly Report on Form 10-Q, Industry 4.0, or I4.0, refers to the integration of advanced technologies into manufacturing and industrial processes to create smart, interconnected systems for improved efficiency and productivity.
Odysight solutions are already deployed in the aviation and medical sectors. Our customers include the Israeli Air Force, the Israeli Ministry of Defense, France-based Safran Aircraft Engines, a global international defense contractor, a leading Fortune 500 medical company as well as NASA, who came back to us for a repeat order. Historically, our revenue stream has been derived mainly from the medical sector. We have secured several contracts for our PdM and CBM systems with major government clients and defense and aviation companies and our backlog as of September 30, 2025 of approximately $14.2 million reflects mostly those contracts.
As we have not received a purchase order for 2025 from the Fortune 500 medical company customer and do not expect to receive such order, we decided, during the first quarter of 2025, to fully derecognize the fulfilment asset and contract liability associated with this customer.
| -21- |
Public Offering and Nasdaq Listing
In February 2025, we closed a public offering, including the exercise of an over-allotment option granted to the underwriter in the public offering. The public offering and the over-allotment option exercise price was $6.50 per share. In the aggregate, we sold a total of 3,653,124 shares of common stock, generating gross proceeds of approximately $23.7 million, prior to the deduction of underwriting discounts, commissions and estimated offering expenses. After deducting issuance costs, we received proceeds of approximately $20.9 million. Also in February 2025, our common stock began trading on the Nasdaq Capital Market under the symbol “ODYS”.
Impact of the Ongoing War in Israel on Our Business
On October 7, 2023, the Hamas terrorist organization launched a series of deadly terror attacks on civilian and military targets skirting the Gaza Strip in the southern part of Israel and fired rockets on many of the communities in southern and central Israel. Following the attack, Israel’s security cabinet declared war and commenced a military campaign in Gaza against Hamas. Following the outbreak of the war, the Hezbollah terrorist organization regularly fired rockets into northern Israel and, in October 2024, Israel invaded southern Lebanon in response to these attacks. On November 27, 2024, Israel and Lebanon agreed to a ceasefire, the result of which is uncertain. During the course of the war, other terrorist organizations have fired rockets into Israel, such as various rebel militia groups in Syria and Iraq and the Houthi movement, which controls parts of Yemen. The Houthis movement has also attacked commercial shipping vessels in the Gulf of Aden and Red Sea. In addition, following two direct attacks by Iran on Israel in 2024 involving hundreds of drones and missiles, the two countries fought a 12-day war in June 2025 that was triggered by large-scale preemptive Israeli airstrikes on Iranian nuclear and military sites. Iran retaliated with significant ballistic missile and drone attacks on Israel, leading to direct U.S. military intervention against Iranian nuclear sites before a U.S.-brokered ceasefire was declared. As of October 9, 2025, Israel and Hamas entered into a ceasefire agreement calling for a permanent end of the war. However, there are no assurances that such as agreement will hold. While the conflict has created heightened security concerns, disruptions to business operations and economic instability, the ceasefire may contribute to improved regional stability. However, the security situation remains fluid, and any renewed military actions, restrictions, or government-imposed measures could adversely affect our operations, supply chains and financial condition.
The war has had significant economic, military and social consequences to Israel. To date the war has not had a material adverse effect on our business. While we have offices in Omer and Ramat Gan, Israel, neither of our sites is located near Israel’s relevant borders where the main impact of the war has been felt. Nevertheless, we have experienced some minor disruptions to our routine work, including some difficulties in traveling outside of Israel and occasional rocket fire on the municipalities where our offices are located, requiring our employees to take temporarily shelter for a few minutes at a time in on-site safe rooms. Pursuant to instructions from Israel’s Home Front Command, the Company’s offices were closed on certain days during the war with Iran. In addition, several of our executives and employees were called up to military reserve duty, including company officers such as our CEO, who until recent months was subject to military reserve duty a few days a month. We have taken various measures to mitigate the effects of the war, including adopting work-from-home measures, increased employee overtime and third-party outsourcing where needed, and reviewing our business continuity plan. In addition, with the backdrop of the ongoing conflict, some of our clients and potential clients have not prioritized conducting transactions with us, and the war may have caused some delays in their finalizing purchase orders. We do not believe that such delays have had a material impact on our business. The war has also increased negative sentiments regarding Israel and Israeli companies in the international community. For example, Israeli defense companies were initially banned from participating in prestigious industry conferences in France during 2024; however, both bans were later overturned by French courts and did not impact our participation in such conferences.
Conversely, as a result of the intensive flight hours flown by all Israeli Air Force platforms as a result of the war and an enhanced Israel Ministry of Defense budget, we have experienced a growing interest in our technology from Israeli clients, including government agencies and R&D programs, which may lead to more rapid assimilation of our technology into relevant platforms than we had anticipated prior to the commencement of the war, positively affecting on our business activity. For additional information, see “Risks Related to our Operations in Israel – Our headquarters and other significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in Israel” in our Annual Report on Form 10-K for the year ended December 31, 2024.
Comparison of the nine months ended September 30, 2025 and 2024
The following table summarizes our results of operations for the nine months period ended September 30, 2025 and 2024, together with the changes in those items in dollars in thousands and as a percentage:
| Nine months ended September 30, | ||||||||||||
| 2025 | 2024 | % Change | ||||||||||
| Revenues | 2,576 | 2,660 | (3 | )% | ||||||||
| Cost of Revenues | 1,882 | 1,964 | (4 | )% | ||||||||
| Gross Profit | 694 | 696 | - | |||||||||
| Research and development expenses | 7,322 | 4,705 | 56 | % | ||||||||
| Sales and marketing expense | 1,604 | 806 | 99 | % | ||||||||
| General and administrative expenses | 5,473 | 3,929 | 39 | % | ||||||||
| Operating Loss | (13,705 | ) | (8,744 | ) | 57 | % | ||||||
| -22- |
Revenues
As a result of the nature of our target market and the current stage of our development, a substantial portion of our revenue comes from a limited number of customers.
Revenues for the nine months ended September 30, 2025 amounted to $2,576 thousand, compared to $2,660 thousand for the nine months ended September 30, 2024.
Revenues for the nine months ended September 30, 2025 were primarily comprised of:
| - | full derecognition of the contract liability associated with the Fortune 500 medical company customer, in the amount of $1.7 million, as described in Note 6(a)(1) to our interim consolidated financial statements for the nine months ended September 30, 2025, and | |
| - | $0.7 million in revenues from our vision-based platform solutions for PdM and CBM. |
Revenues for the nine months ended September 30, 2024 were primarily comprised of:
| - | $2.0 million in revenues from products sold to the Fortune 500 medical company customer, and | |
| - | $0.6 million in revenues from our vision-based platform solutions for PdM and CBM. |
Cost of Revenues
Cost of revenues is primarily comprised of cost of personnel, certain allocated expenses related to facilities, logistics and quality control.
Cost of revenues for the nine months ended September 30, 2025 was $1,882 thousand, a decrease of $82 thousand, or 4%, compared to cost of revenues of $1,964 thousand for the nine months ended September 30, 2024.
The decrease in cost of revenues is consistent with the decrease in revenues, as described above.
Gross Profit
Gross profit for the nine months ended September 30, 2025, was $694 thousand, a decrease of $2 thousand, compared to gross profit of $696 thousand for the nine months ended September 30, 2024.
The decrease in cost of revenues was due to the decrease in revenues partially offset by the decrease in cost of revenues, as described above.
Research and Development Expenses
Research and development efforts are focused on new product development and on developing additional functionality for our new and existing products. These expenses primarily consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel engaged in research and development functions, consulting, and professional fees related to research and development activities, prototype materials, facility costs and other allocated expenses, including expenses for rent and maintenance of our facilities, utilities, depreciation and other supplies. We expense research and development costs as incurred.
Research and development expenses for the nine months ended September 30, 2025, were $7,322 thousand, an increase of $2,617 thousand, or 56%, compared to $4,705 thousand for the nine months ended September 30, 2024.
The increase in research and development expenses was mainly due to the development of new products and the resulting increase in payroll and related expenses related to the recruitment of new employees, an increase in stock-based compensation from new option grants and procuring materials and services of subcontractors for Industry 4.0 projects.
We expect that our research and development expenses will increase as we continue to develop our products and services and recruit additional research and development employees due to increased focus on R&D activities in the I4.0 domain.
| -23- |
Sales and Marketing Expenses
Sales and marketing expenses primarily consist of payroll and related expenses, consulting services, promotional materials, exhibitions, demonstration equipment and certain allocated facility infrastructure costs.
Sales and marketing expenses for the nine months ended September 30, 2025, were $1,604 thousand, an increase of $798 thousand, or 99%, compared to $806 thousand for the nine months ended September 30, 2024.
The increase in sales and marketing expenses was primarily driven by our enhanced selling and marketing activity, including efforts to penetrate new markets and verticals, and enhance product visibility. This led to higher payroll and related expenses associated with the recruitment of new employees and an increase in additional expenses resulting from the engagement of new marketing consultants.
We expect that our sales and marketing expenses will increase as we expand our selling and marketing efforts in the I4.0 domain
General and Administrative Expenses
General and administrative expenses primarily consist of salaries and other related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor, public relations, accounting, auditing, tax services and insurance costs.
General and administrative expenses for the nine months ended September 30, 2025, were $5,473 thousand, an increase of $1,544 thousand, or 39%, compared to $3,929 thousand for the nine months ended September 30, 2024.
The increase in general and administrative expenses was primarily due to:
| - | an increase in payroll and related expenses due to the recruitment of new employees, including a CFO, and cash compensation bonuses paid to senior executives; | |
| - | expenses related to our fund raising and uplisting to Nasdaq; and | |
| - | an increase in stock-based compensation from new option grants. |
Operating loss
We incurred an operating loss of $13,705 thousand for the nine months ended September 30, 2025, an increase of $4,961 thousand or 57%, compared to operating loss of $8,744 thousand for the nine months ended September 30, 2024.
The increase in operating loss was due to increases in research and development expenses, general and administrative expenses and sales and marketing expenses, each as described above.
Cash Flows
Our primary uses of cash used in operating activities have been for payroll expenses, research and development costs, manufacturing costs, marketing and promotional expenses, professional services costs and costs related to our facilities. We expect that cash flows from operating activities will continue to increase due to an expected increase in the expenses of our business and our working capital requirements.
The following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars in thousands):
| Nine months ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| Cash used in Operating Activity | (9,821 | ) | (5,522 | ) | ||||
| Cash provided by Investing Activity | 269 | 7,962 | ||||||
| Cash provided by Financing Activity | 21,057 | 9,850 | ||||||
Operating Activities
During the nine months ended September 30, 2025, cash used in operating activities was $9.8 million, consisting of net loss of $12.8 million, partially offset by a favorable net change in operating assets and liabilities of $0.3 million and a non-cash benefit of $2.6 million. Our non-cash benefit consisted primarily of non-cash charges for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash inflows from changes in accounts receivable and a decrease in contract fulfilment assets, partially offset by outflows from changes in current and non-current contract liabilities.
During the nine months ended September 30, 2024, cash used in operating activities was $5.5 million, consisting of net loss of $8.2 million, partially offset by a favorable net change in operating assets and liabilities of $1 million and a non-cash benefit of $1.7 million. Our non-cash benefit consisted primarily of non-cash charges for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash inflows from changes in accounts receivable and accrued compensation expenses, partially offset by outflows from changes in current and non-current other assets and contract liabilities.
| -24- |
Investing Activities
During the nine months ended September 30, 2025, net cash provided by investing activities was $0.3 million, consisting mainly of a withdrawal of short-term deposits.
During nine months ended September 30, 2024, net cash flows provided by investing activities was $8 million, consisting mainly of a withdrawal of short-term deposits.
Financing Activities
During the nine months ended September 30, 2025, cash provided by financing activities was $21.1 million, consisting of cash proceeds from issuance of shares, net of issuance costs and proceeds from options exercise.
During the nine months ended September 30, 2024, cash provided by financing activities was $9.9 million, consisting of cash proceeds from issuance of shares, net of issuance costs.
Comparison of the three months ended September 30, 2025 and 2024
The following table summarizes our results of operations for the three months period ended September 30, 2025, and 2024, together with the changes in those items in dollars in thousands and as a percentage:
| Three months ended September 30, | ||||||||||||
| 2025 | 2024 | % Change | ||||||||||
| Revenues | 149 | 1,292 | (88 | )% | ||||||||
| Cost of Revenues | 126 | 887 | (86 | )% | ||||||||
| Gross Profit | 23 | 405 | (94 | )% | ||||||||
| Research and development expenses | 2,479 | 1,730 | 43 | % | ||||||||
| Sales and marketing expense | 580 | 347 | 67 | % | ||||||||
| General and administrative expenses | 1,671 | 1,344 | 24 | % | ||||||||
| Operating Loss | (4,707 | ) | (3,016 | ) | 56 | % | ||||||
Revenues
As a result of the nature of our target market and the current stage of our development, a substantial portion of our revenue comes from a limited number of customers.
For the three months ended September 30, 2025, we generated revenues of $149 thousand, a decrease of $1,143 thousand, or 88%, compared to $1,292 thousand for the three months ended September 30, 2024.
The decrease in revenues was primarily attributable to the decrease in revenues from the Fortune 500 medical company customer.
Cost of Revenues
Cost of revenues is primarily comprised of cost of personnel, certain allocated expenses related to facilities, logistics and quality control.
Cost of revenues for the three months ended September 30, 2025, was $126 thousand, a decrease of $761 thousand, or 86%, compared to cost of revenues of $887 thousand for the three months ended September 30, 2024.
The decrease in cost of revenues was mainly due to the decrease in revenues, as described above.
Gross Profit
Gross profit for the three months ended September 30, 2025, was $23 thousand, a decrease of $382 thousand, or 94%, as compared to the three months ended September 30, 2024.
The change in gross profit was due to both the decrease in revenues and the decrease in cost of revenues, as described above.
| -25- |
Research and Development Expenses
Research and development efforts are focused on new product development and on developing additional functionality for our new and existing products. These expenses primarily consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel engaged in research and development functions, consulting and professional fees related to research and development activities, prototype materials, facility costs and other allocated expenses, including expenses for rent and maintenance of our facilities, utilities, depreciation and other supplies. We expense research and development costs as incurred.
Research and development expenses for the three months ended September 30, 2025 were $2,479 thousand, an increase of $749 thousand, or 43%, compared to $1,730 thousand for the three months ended September 30, 2024.
The increase in research and development expenses was mainly due to the development of new products and the resulting increase in payroll and related expenses for new employees’ recruitment and an increase in stock-based compensation from new option grants.
We expect that our research and development expenses will increase as we continue to develop our products and services and recruit additional research and development employees due to increased focus on R&D activities in the I4.0 domain
Sales and Marketing Expenses
Sales and marketing expenses primarily consist of payroll and related expenses, consulting services, promotional materials, exhibitions, demonstration equipment and certain allocated facility infrastructure costs.
Sales and marketing expenses for the three months ended September 30, 2025, were $580 thousand, an increase of $233 thousand, or 67%, compared to $347 thousand for the three months ended September 30, 2024.
The increase in sales and marketing expenses was primarily driven by our enhanced selling and marketing activity, including efforts to penetrate new markets and verticals and enhance product visibility. This led to higher payroll and related expenses associated with the recruitment of new employees and additional expenses resulting from the engagement of new marketing consultants.
We expect that our sales and marketing expenses will increase as we expand our selling and marketing efforts in the I4.0 domain
General and Administrative Expenses
General and administrative expenses primarily consist of salaries and other related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor, public relations, accounting, auditing, tax services and insurance costs.
General and administrative expenses for the three months ended September 30, 2025, were $1,671 thousand, an increase of $327 thousand, or 24% compared to $1,344 thousand for the three months ended September 30, 2024.
The increase in general and administrative expenses was primarily due to an increase in stock-based compensation from new option grants and an increase in professional services costs.
Operating loss
We incurred an operating loss of $4,707 thousand for the three months ended September 30, 2025, an increase of $1,691 thousand, or 56%, compared to operating loss of $3,016 thousand for the three months ended September 30, 2024.
The increase in operating loss was due to decreases in gross profit and increases in research and development expenses, sales and marketing expenses and general and administrative expenses, each as described above.
| -26- |
Cash Flows
Our primary uses of cash used in operating activities have been for payroll expenses, research and development costs, manufacturing costs, marketing and promotional expenses, professional services costs and costs related to our facilities. We expect that cash flows from operating activities will continue to increase due to an expected increase in the expenses of our business and our working capital requirements.
The following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars in thousands):
| Three months ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| Cash used in Operating Activity | (3,418 | ) | (2,199 | ) | ||||
| Cash used in Investing Activity | (11 | ) | (8 | ) | ||||
| Cash provided by Financing Activity | 1 | 9,850 | ||||||
Operating Activities
During the three months ended September 30, 2025, cash used in operating activities was $3.4 million, consisting of net loss of $4.4 million and a non-cash benefit of $1 million. Our non-cash benefit consisted primarily of non-cash charges of $0.9 million for stock-based compensation.
During the three months ended September 30, 2024, cash used in operating activities was $2.2 million, consisting of net loss of $2.9 million, a favorable net change in operating assets and liabilities of $0.1 million and a non-cash benefit of $0.5 million. Our non-cash benefit consisted primarily of non-cash charges of $0.5 million for stock-based compensation.
Investing Activities
For the three months ended September 30, 2025, net cash flows used in investing activities was $11 thousand, attributable to a purchase of property and equipment.
For the three months ended September 30, 2024, net cash flows provided by investing activities was $8 million, attributable to a purchase of property and equipment.
Financing Activities
For the three months ended September 30, 2025, net cash flows provided by financing activities was $1 thousand, consisting of proceeds from options exercise, partially offset by issuance expenses.
Backlog
Backlog represents booked orders based on purchase orders or hard commitments but not yet recognized as revenue. Orders included in backlog may be cancelled or rescheduled by customers. A variety of conditions, both specific to the individual customer and generally affecting the customer’s industry, may cause customers to cancel, reduce or delay orders that were previously made or anticipated. We cannot assure the timely replacement of cancelled, delayed or reduced orders. Backlog is presented for supplemental informational purposes only and is not intended to be a substitute for any GAAP financial measures, including revenue or net income (loss), and, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. In addition, backlog should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Therefore, backlog should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP.
Our backlog as of September 30, 2025 was approximately $14.2 million compared to approximately $15.0 million as of December 31, 2024.
Liquidity and Capital Resources
As of September 30, 2025, we had cash and cash equivalents and restricted cash of $29.8 million compared to cash and cash equivalents and restricted deposit of $18.5 million as of December 31, 2024. In addition, as of September 30, 2025, we incurred an accumulated deficit of $58.7 million compared to $46 million as of December 31, 2024.
In February 2025, we closed a public offering, including the exercise of an over-allotment option granted to the underwriter in the public offering, at a price of $6.50 per share. In the aggregate, we issued 3,653,124 shares of common stock, generating gross proceeds of approximately $23.7 million, prior to the deduction of underwriting commissions and estimated offering expenses.
Our primary sources of liquidity to date have been from fund-raising, revenues from customers and warrant exercises.
Additional Cash Requirements
We plan to continue to invest in long-term growth, and therefore we expect that our expenses will grow. We currently believe that our existing cash and cash equivalents and short-term deposits will allow us to fund our operating plan through at least the next 12 months from the date of this report. We expect our expenses will increase in connection with our ongoing activities, particularly as we continue the research and development and the scale up Odysight TruVision solutions. We expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. Accordingly, we may need to raise additional capital before we become profitable from sales of our solutions and may do so to expand our business, pursue strategic investments, take advantage of financing opportunities or for other reasons. We may raise these funds through equity financing, debt financing or other sources, which may result in further dilution in the equity ownership of our common stock. There is no assurance that we will be able to maintain operations at a level sufficient for investors to obtain a return on their investment in our common stock, or that we will be able to raise sufficient capital required to implement our business plan on acceptable terms, if at all. Even if we are successful in raising sufficient capital to implement our business plan, we will, most likely, continue to be unprofitable for the foreseeable future. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.
| -27- |
Contractual Obligations and Commitments
Operating lease payments represent our commitment for future rent made leases for our offices in Israel and for vehicle leasing. The total future payments for our operating lease obligation as of September 30, 2025 were approximately $0.9 million. For additional details regarding our lease, see Note 3 to our interim consolidated financial statements for the nine months ended September 30, 2025.
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
As a smaller reporting company, we are not required to provide the information requested by this Item.
Item 4. Controls and Procedures.
Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Exchange Act Rule 13a-15(e). Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.
No change in our internal control over financial reporting, as defined in Exchange Act Rule 13a-15(e), occurred during the fiscal quarter ended September 30, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
| -28- |
PART II- OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.
ITEM 1A. RISK FACTORS.
There have been no material changes from the information set forth either in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 26, 2025, or in “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, as filed with the SEC on August 13, 2025.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
During the three months ended September 30, 2025, we did not have any sales of unregistered securities.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURE
Not applicable.
ITEM 5. OTHER INFORMATION
During
the quarter ended September 30, 2025, no director or officer of the Company
| -29- |
ITEM 6. EXHIBITS.
| (a) | The following documents are filed as exhibits to this Quarterly Report or incorporated by reference herein. |
Exhibit Number |
Description | |
| 3.1.1 | Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1.1 to our Form S-1 filed with the SEC on July 17, 2023) | |
| 3.2.1 | Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed with the SEC on June 8, 2023) | |
| 31.1* | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act | |
| 31.2* | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act | |
| 32.1** | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 32.2** | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 101.INS | Inline XBRL Instance Document | |
| 101.INS | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) | |
| * | Filed herewith. | |
| ** | Furnished herewith. |
| -30- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 12, 2025 | ODYSIGHT.AI INC | |
| By: | /s/ Yehu Ofer | |
| Name: | Yehu Ofer | |
| Title: | Chief Executive Officer | |
| Odysight.ai Inc | ||
| By: | /s/ Einav Brenner | |
| Name: | Einav Brenner | |
| Title: | Chief Financial Officer | |
| Odysight.ai Inc | ||
| -31- |
FAQ
What was Odysight.ai (ODYS) Q3 2025 revenue and net loss?
How did nine-month 2025 results compare year over year for ODYS?
What drove the 2025 revenue and margin mix at Odysight.ai?
What were ODYS operating expenses for the nine months ended Sept 30, 2025?
How much cash did Odysight.ai have at Sept 30, 2025?
What capital raise did ODYS complete in 2025?
What is Odysight.ai’s backlog/remaining performance obligations?
